These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20938822)

  • 41. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer.
    Brake M; Loertzer H; Horsch R; Keller H
    Urology; 2000 May; 55(5):673-8. PubMed ID: 10792077
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Nonmuscle-invasive bladder cancer (NMIBC): when to perform cystectomy?].
    Lebret T
    Prog Urol; 2008 May; 18 Suppl 5():S111-4. PubMed ID: 18585632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer.
    Matsumoto K; Kikuchi E; Shirakawa H; Hayakawa N; Tanaka N; Ninomiya A; Miyajima A; Nakamura S; Oya M
    BJU Int; 2012 Dec; 110(11 Pt B):E508-13. PubMed ID: 22574662
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer.
    Steinberg RL; Brooks NA; Thomas LJ; Mott SL; O'Donnell MA
    Urol Oncol; 2017 May; 35(5):201-207. PubMed ID: 28041998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience.
    Pansadoro V; Emiliozzi P; de Paula F; Scarpone P; Pansadoro A; Sternberg CN
    Urology; 2002 Feb; 59(2):227-31. PubMed ID: 11834391
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Urinary bladder carcinoma - research subject recruitment!].
    Aktuelle Urol; 2014 May; 45(3):170-2. PubMed ID: 24932550
    [No Abstract]   [Full Text] [Related]  

  • 50. Prospective phase II trial of alternating intravesical Bacillus Calmette-Guérin (BCG) and interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder: preliminary results.
    Bazarbashi S; Raja MA; El Sayed A; Ezzat A; Ibrahim E; Kattan S; Kardar A; Peracha A; Lindstedt E; Hanash K
    J Surg Oncol; 2000 Jul; 74(3):181-4. PubMed ID: 10951412
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success.
    Lebret T; Gaudez F; Hervé JM; Barré P; Lugagne PM; Botto H
    Eur Urol; 1998; 34(1):67-72. PubMed ID: 9676417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.
    Duchek M; Johansson R; Jahnson S; Mestad O; Hellström P; Hellsten S; Malmström PU;
    Eur Urol; 2010 Jan; 57(1):25-31. PubMed ID: 19819617
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Controversies in the management of T1 urothelial bladder cancer.
    Azzouz H; Cauberg EC; De Reijke TM
    Minerva Urol Nefrol; 2011 Dec; 63(4):309-15. PubMed ID: 21996986
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
    Luciani LG; Neulander E; Murphy WM; Wajsman Z
    Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach.
    Schulze M; Stotz N; Rassweiler J
    J Endourol; 2007 Dec; 21(12):1533-41. PubMed ID: 18186695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnosis and management of superficial bladder cancer.
    Amling CL
    Curr Probl Cancer; 2001; 25(4):219-78. PubMed ID: 11514784
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    Lotan Y; Inman BA; Davis LG; Kassouf W; Messing E; Daneshmand S; Canter D; Marble HT; Joseph AM; Jewell S; Boorjian SA
    J Urol; 2019 Nov; 202(5):920-926. PubMed ID: 31120373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.